Latest News - IDEXX Laboratories
Top Corporates Hub
IDEXX Laboratories
ALC vs. IDXX: Which Stock Is the Better Value Option?
07.07.2026 15:40
ALC vs. IDXX: Which Stock Is the Better Value Option?
IDEXX Laboratories Does Not Need More Vet Visits--But It Needs More Tests Per Visit
07.07.2026 07:58
IDEXX Laboratories (IDXX) is rated Hold, as its premium valuation (~38x 2026E EPS) already assumes strong recurring revenue and diagnostics growth.
IDEXX Laboratories to Release 2026 Second Quarter Financial Results
01.07.2026 20:00
WESTBROOK, Maine, July 01, 2026--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 second quarter financial results for Tuesday, August 4, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day.
Could Insulet’s (PODD) Russell 2500 Debut Quietly Reframe the Omnipod Investment Narrative?
30.06.2026 17:06
Insulet Corporation was recently added to both the Russell 2500 Index and the Russell 2500 Growth Benchmark, and earlier this week appointed former IDEXX Laboratories chief executive Jonathan (“Jay”) Mazelsky as an independent director to its board, effective July 1, 2026. These index inclusions can attract passive fund inflows and broader institutional attention, while Mazelsky’s extensive healthcare and diagnostics background may influence Insulet’s oversight and long-term strategic...
Insulet (PODD) Appoints Jay Mazelsky To Its Board Of Directors
30.06.2026 05:05
Insulet (NasdaqGS:PODD) has appointed Jay Mazelsky to its Board of Directors. Mazelsky brings executive and board experience from IDEXX Laboratories and Philips Healthcare. The appointment adds healthcare technology and governance expertise to Insulet's boardroom. For investors following Insulet, a company focused on insulin delivery technology, board composition is an important part of the story. The addition of Jay Mazelsky connects Insulet with leadership experience from established...
A Small Upgrade Could Have a Big Impact for IDEXX Customers
22.06.2026 13:31
With a short percentage of shares outstanding of 2.76%, IDEXX Laboratories, Inc. (NASDAQ:IDXX) is among the 7 Best Pet Care Stocks to Buy for Consistent Recurring Revenue. On May 26, IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced the expansion of its Fecal Dx antigen testing platform to include detection of taeniid tapeworm species, including Taenia and Echinococcus. The enhanced testing capability is […]
Idexx (IDXX) Down 3.2% Since Last Earnings Report: Can It Rebound?
04.06.2026 15:30
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IDEXX Laboratories Touts AI Push, inVue Dx Momentum at Stifel Conference
30.05.2026 11:02
IDEXX Laboratories (NASDAQ:IDXX) President and CEO Michael Erickson used a Stifel investor conference appearance to emphasize the company’s innovation pipeline, expanding commercial reach and growing use of software and artificial intelligence across veterinary diagnostics. Erickson, who recently b
IDEXX Laboratories, Inc. (IDXX) Presents at Stifel Jaws & Paws Conference 2026 Transcript
27.05.2026 13:27
IDEXX Laboratories, Inc. (IDXX) Stifel Jaws & Paws Conference 2026 May 27, 2026 10:55 AM EDTCompany ParticipantsMichael Erickson - CEO, President &...
IDEXX Expands Fecal Dx Antigen Testing Platform with Taeniid Tapeworm Detection
26.05.2026 11:00
WESTBROOK, Maine, May 26, 2026--IDEXX expands Fecal Dx™ antigen testing with taeniid tapeworm detection for broader intestinal parasite screening in wellness and sick-pet care.
IDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles
19.05.2026 11:00
WESTBROOK, Maine, May 19, 2026--IDEXX integrates SDMA into most common Catalyst chemistry profiles, enabling earlier detection of kidney disease through routine in‑clinic testing.
IDEXX Laboratories Q1 Earnings Call Highlights
05.05.2026 19:27
IDEXX Laboratories (NASDAQ:IDXX) reported first-quarter 2026 results that management described as an “exceptional start” to the year, driven by continued execution in its companion animal business and contributions from recent innovations. First-quarter results driven by companion animal diagnostic
IDEXX Laboratories, Inc. Q1 2026 Earnings Call Summary
05.05.2026 16:51
Moby summary of IDEXX Laboratories, Inc.'s Q1 2026 earnings call
Idexx (IDXX) Q1 2026 Earnings Call Transcript
05.05.2026 16:19
During the first quarter, IDEXX delivered exceptional financial results through continued execution in our companion animal business with benefits from IDEXX innovations. Revenue increased 14% as reported and 11% organically supported by over 11% organic growth in CAG Diagnostics recurring revenues, reflecting nearly 11% gains in the U.S. and approximately 12% growth in international regions. CAG Diagnostic recurring revenue growth in Q1 was negatively impacted by declines in U.S. same-store clinical visits of approximately 1%, with slightly positive growth in non-well visits more than offset by pressure on wellness visits.
How Fluffy's Testing Service Outplayed Slow Vet Visits — Again
05.05.2026 16:18
Idexx stock clawed higher Tuesday as the pet-health company delivered better-than-expected first-quarter sales, outmaneuvering — again — weak vet visit numbers.
IDEXX Laboratories, Inc. 2026 Q1 - Results - Earnings Call Presentation
05.05.2026 15:02
2026-05-05. The following slide deck was published by IDEXX Laboratories, Inc.
IDEXX Stock Up on Q1 Earnings & Revenue Beat, Margins Rise, '26 View Up
05.05.2026 14:28
IDXX rides strong on Q1 beats with rising margins; lifts 2026 outlook as diagnostics growth and innovation momentum fuel performance.
IDEXX Laboratories, Inc. (IDXX) Q1 2026 Earnings Call Transcript
05.05.2026 14:11
IDEXX Laboratories, Inc. (IDXX) Q1 2026 Earnings Call May 5, 2026 8:30 AM EDTCompany ParticipantsAndrew Emerson - Executive VP, CFO & TreasurerJay...
Idexx (IDXX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
05.05.2026 13:30
The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Is It Too Late To Consider IDEXX Laboratories (IDXX) After Its 18.5% One-Year Rally?
05.05.2026 13:20
If you are wondering whether IDEXX Laboratories at around US$563 per share looks expensive, cheap or somewhere in between, this article walks through key valuation checks to help you frame that question for yourself. The stock is up 18.5% over the past year. However, the year to date return of 16.0% and recent 7 day and 30 day returns of 2.1% and 1.1% show that the ride has not been in a straight line. Recent attention on IDEXX Laboratories has centered on how investors are weighing long...